medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2016, Number 3

<< Back Next >>

Acta Med 2016; 14 (3)

Progress and challenges in the pathophysiology and treatment of nephrolithiasis

Peña RJC

Language: Spanish
References: 53
Page: 155-161
PDF size: 150.49 Kb.


ABSTRACT

This review show the high incidence and prevalence of nephrolithiasis in the general population. Recent epidemiological studies demonstrate that renal stone formation is associated with other chronic diseases, all of them, risk factors for cardiovascular and renal damage; these results suggests that stone formation is more a systemic disease with organic repercussions. We discuss the medical therapies for the management of stone passage; and also the recently described Rule et al Nomogram, for the prediction of recurrence of stones episodes. The drugs employed for the treatment of this disease are mentioned, as well as the use of diet and increase in fluid intake. Before treatment, it is critical to establish the metabolic abnormalities in active stone formers. The formation of Randall plaque is described in patients with hypercalciuria as the site of deposition of calcium oxalate crystals. The treatment of hyperuricosuria with alopurinol and flebuxostat and the rol of citrate in the control of calcium an uric acid stones is evaluated; as well as the mechanisms and treatment of renal stones in cystinuria.


REFERENCES

  1. Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Samuel S, Klarenbach SW et al. Kidney stones and cardiovascular events: a cohort study. Clin J Am Soc Nephrol. 2014; 9 (3): 506-512.

  2. Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S et al. Kidney stones and kidney function loss: a cohort study. BMJ. 2012; 345: e5287.

  3. Rule AD, Roger VL, Melton LJ 3rd, Bergstralh EJ, Li X, Peyser PA et al. Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol. 2010; 21 (10): 1641-1644.

  4. Obligado SH, Goldfarb DS. The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens. 2008; 21 (3): 257-264.

  5. Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4 (4): 804-811.

  6. Aydin H, Yencilek F, Erihan IB, Okan B, Sarica K. Increased 10-year cardiovascular disease and mortality risk scores in asymptomatic patients with calcium oxalate urolithiasis. Urol Res. 2011; 39 (6): 451-458.

  7. Reiner AP, Kahn A, Eisner BH, Pletcher MJ, Sadetsky N, Williams OD et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J Urol. 2011; 185 (3): 920-925.

  8. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005; 68 (3): 1230-1235.

  9. Rule AD, Lieske JC, Li X, Melton LJ 3rd, Krambeck AE, Bergstralh EJ. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol. 2014; 25 (12): 2878-2886.

  10. Eisner BH, Goldfarb DS. A nomogram for the prediction of kidney stone recurrence. J Am Soc Nephrol. 2014; 25 (12): 2685-2687.

  11. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996; 155 (3): 839-843.

  12. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002; 346 (2): 77-84.

  13. Dellabella M, Milanese G, Muzzonigro G. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. Urology. 2005; 66 (4): 712-715.

  14. Parsons JK, Hergan LA, Sakamoto K, Lakin C. Efficacy of alpha-blockers for the treatment of ureteral stones. J Urol. 2007; 177 (3): 983-987; discussion 987.

  15. Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck C, Gallucci M et al. 2007 guideline for the management of ureteral calculi. J Urol. 2007; 178 (6): 2418-2434.

  16. Coe FL, Evan A, Worcester E. Pathophysiology-based treatment of idiopathic calcium kidney stones. Clin J Am Soc Nephrol. 2011; 6 (8): 2083-2092.

  17. Renkema KY, Bindels RJ, Hoenderop JG. Role of the calcium-sensing receptor in reducing the risk for calcium stones. Clin J Am Soc Nephrol. 2011; 6 (8): 2076-2082.

  18. Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol. 1988; 139 (4): 679-684.

  19. Ohkawa M, Tokunaga S, Nakashima T, Orito M, Hisazumi H. Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol. 1992; 69 (6): 571-576.

  20. Peña JC, Monforte MF, Briceño A. The role of oxalate and calcium oxalate activity and formation product ratio in patients with renal stones before and during treatment. J Urol. 1987; 138 (5): 1137-1140.

  21. Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol. 1993; 22 Suppl 6: S78-S86.

  22. Yendt ER, Guay GF, García DA. The use of thiazides in the prevention of renal calculi. Can Med Assoc J. 1970; 102 (6): 614-620.

  23. Coe FL, Favus MJ, Pak CY, Parks JH, Preminger GM, Ettinger B. Hyperuricosuric calcium stone disease and mixed stones. In: Kidney Stones: Medical and Surgical Management, edited by Coe FL, Favus MJ, Pak CY, Parks JH, Preminger GM. Philadelphia: Lippincott-Raven; 1996. pp. 851-858.

  24. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med. 1977; 87 (4): 404-410.

  25. Ryall RL, Grover PK, Marshall VR. Urate and calcium stones-picking up a drop of mercury with one’s fingers? Am J Kidney Dis. 1991; 17 (4): 426-430.

  26. Grover PK, Marshall VR, Ryall RL. Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: implications for calcium oxalate stone genesis. Chem Biol. 2003; 10 (3): 271-278.

  27. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008; 73 (4): 489-496.

  28. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986; 315 (22): 1386-1389.

  29. Ettinger B. Does hyperuricosuria play a role in calcium oxalate lithiasis? J Urol. 1989; 141 (3 Pt 2): 738-741.

  30. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005; 12 (1): 22-34.

  31. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353 (23): 2450-2461.

  32. Goldfarb DS. Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria. Clin J Am Soc Nephrol. 2011; 6 (8): 2093-2097.

  33. Rodgers A, Allie-Hamdulay S, Jackson G. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant. 2006; 21 (2): 361-369.

  34. Hess B, Zipperle L, Jaeger P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol. 1993; 265 (6 Pt 2): F784-F791.

  35. Reddy ST, Wang CY, Sakhaee K. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis. 2002; 40 (2): 265-274.

  36. Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf. 2007; 6 (5): 547-557.

  37. Warner BW, LaGrange CA, Tucker T, Bensalem-Owen M, Pais VM Jr. Induction of progressive profound hypocitraturia with increasing doses of topiramate. Urology. 2008; 72 (1): 29-32; discussion 32-33.

  38. Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis. 2006; 48 (4): 555-563.

  39. Melnick JZ, Preisig PA, Haynes S, Pak CY, Sakhaee K, Alpern RJ. Converting enzyme inhibition causes hypocitraturia independent of acidosis or hypokalemia. Kidney Int. 1998; 54 (5): 1670-1674.

  40. Shey J, Cameron MA, Sakhaee K, Moe OW. Recurrent calcium nephrolithiasis associated with primary aldosteronism. Am J Kidney Dis. 2004; 44 (1): e7-12.

  41. Seltzer MA, Low RK, McDonald M. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol. 1996; 156 (3): 907-909.

  42. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol. 1993; 150 (6): 1761-1764.

  43. Pak CY, Fuller C, Sakhaee K. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol. 1985; 134 (1): 11-19.

  44. Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol. 2010; 6 (7): 424-434.

  45. Mattoo A, Goldfarb DS. Cystinuria. Semin Nephrol. 2008; 28 (2): 181-191.

  46. Goldfarb DS, Coe FL, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int. 2006; 69 (6): 1041-1047.

  47. Crawhall JC, Scowen EF, Watts RW. Effect of penicillamine on cystinuria. Br Med J. 1963; 1 (5330): 588-590.

  48. Dahlberg PJ, van den Berg, Kurtz SB, Wilson DM, Smith LH. Clinical features and management of cystinuria. Mayo Clin Proc. 1977; 52 (9): 533-542.

  49. Rodríguez LM, Santos F, Málaga S, Martínez V. Effect of a low sodium diet on urinary elimination of cystine in cystinuric children. Nephron. 1995; 71 (4): 416-418.

  50. Rodman JS, Blackburn P, Williams JJ, Brown A, Pospischil MA, Peterson CM. The effect of dietary protein on cystine excretion in patients with cystinuria. Clin Nephrol. 1984; 22 (6): 273-278.

  51. Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol. 1986; 136 (5): 1003-1008.

  52. Munday R. Toxicity of thiols and disulphides: involvement of free-radical species. Free Radic Biol Med. 1989; 7 (6): 659-673.

  53. Peña JC, Sáenz S. Manejo farmacológico de la nefrolitiasis. NEFROMECUM. Editores: Correa-Rotter R, Niño-Cruz JA. Cap. 9. Barcelona, España: Publicaciones Permanyer; 2009. pp. 105-116.




2020     |     www.medigraphic.com